Expertise in
16
conditions

Dr. Minetta Liu

Oncology
Mayo Clinic-Rochester
5716 Cleveland St Ste 200, 
Virginia Beach, VA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
16
conditions
Mayo Clinic-Rochester
5716 Cleveland St Ste 200, 
Virginia Beach, VA 

Overview

Minetta Liu is an Oncologist in Virginia Beach, Virginia. Dr. Liu is highly rated in 16 conditions, according to our data. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Paget Disease of the Breast, Virilizing Ovarian Tumor, and Percutaneous Coronary Intervention (PCI).

Her clinical research consists of co-authoring 195 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in DC

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

Mayo Clinic-Rochester
5716 Cleveland St Ste 200, Virginia Beach, VA 23462

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer
Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer
Enrollment Status: Recruiting
Publish Date: January 08, 2026
Intervention Type: Procedure, Biological
Study Drug: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein
Study Phase: Phase 1
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Enrollment Status: Recruiting
Publish Date: May 02, 2025
Intervention Type: Drug, Biological
Study Drugs: Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib, Utomilumab
Study Phase: Phase 2
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: January 29, 2026
Intervention Type: Procedure, Other
A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2026
Intervention Type: Drug
Study Drugs: Niraparib, Trastuzumab
Study Phase: Phase 1/Phase 2
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Drug, Procedure
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Drug
Study Drugs: Ladiratuzumab vedotin, Trastuzumab
Study Phase: Phase 1
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

195 Total Publications

The C-terminus of infectious bursal disease virus VP3 encodes a predicted intrinsically disordered region, which promotes the formation of cytoplasmic puncta and modulates their physical properties.
The C-terminus of infectious bursal disease virus VP3 encodes a predicted intrinsically disordered region, which promotes the formation of cytoplasmic puncta and modulates their physical properties.
Journal: mBio
Published: January 12, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Grace Dy
Oncology
Expertise in
15
conditions
Dr. Grace Dy
Oncology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (988.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Grace Dy is an Oncologist in Virginia Beach, Virginia. Dr. Dy is highly rated in 15 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Lymphadenectomy.

Expertise in
37
conditions
Dr. Ryan Law
Oncology
Expertise in
37
conditions
Dr. Ryan Law
Oncology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (988.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Ryan Law is an Oncologist in Virginia Beach, Virginia. Dr. Law is highly rated in 37 conditions, according to our data. His top areas of expertise are Bile Duct Obstruction, Cholestasis, Hereditary Pancreatitis, Endoscopy, and Gastric Bypass.

Expertise in
14
conditions
Dr. Joleen Hubbard
Oncology
Expertise in
14
conditions
Dr. Joleen Hubbard
Oncology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (988.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joleen Hubbard is an Oncologist in Virginia Beach, Virginia. Dr. Hubbard is highly rated in 14 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Familial Pancreatic Cancer, and Hepato-Pancreato-Biliary Surgery.

Frequently Asked Questions about Dr. Minetta Liu

How do I make an appointment with Dr. Minetta Liu?

You can book an appointment with Dr. Minetta Liu by calling their office at 507-284-2511. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Minetta Liu a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Minetta Liu is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Minetta Liu specialize in?

While Dr. Minetta Liu is a Oncology, they have specific expertise in Breast Cancer, Triple-Negative Breast Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Minetta Liu participate in research or clinical trials?

Yes. Dr. Minetta Liu has published 195 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Minetta Liu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Minetta Liu accept my insurance?

Dr. Minetta Liu accepts most major insurance plans, including Cigna. We recommend calling the office directly at 507-284-2511 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Liu's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile